BioNTech and Pfizer request authorization from the EMA to vaccinate adolescents

The effectiveness of the vaccine between 12 and 15 years was 100% and with a “strong” immune response

Vials with the Pfizer BioNTech vaccine.
Vials with the Pfizer BioNTech vaccine.

The pharmaceutical companies BioNTech and Pfizer have asked the European Medicines Agency (EMA) to extend the authorization of their coronavirus vaccine to adolescents between 12 and 15 years old , both companies reported today.

In a joint statement, they explain that they tested their formula against the coronavirus in 2,260 adolescents in phase three and that, as they announced at the end of March, the effectiveness of the vaccine was 100% and with a “solid” immune response.

The German BioNTech and the American Pfizer also indicate that they have already taken a similar step in the United States , where they have requested that their current emergency permit be adapted, and that they plan to request the same in other districts.

What do you think?

Written by Geekybar

Linguist-translator by education. I have been working in the field of advertising journalism for over 10 years.

For over 7 years in journalism. Half of them are as editor. My weakness is doing mini-investigations on new topics.


Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

ezgif 3 a280ee5cfff6

Netflix: Shadow and Bone, the new series based on a fantasy literary saga

mia khalifa

Her Spanish is perfect! Mia Khalifa surprises singing Bad Bunny song